Besides chemotherapy and immunotherapy, targeted therapy against oncogenic KRAS, the most important driver mutation in pancreatic cancer, has attracting amounts attention from oncologists and pharmacologists for over three decades. Here, KRAS is linked to familial pancreatic carcinoma.